



Universiteit  
Leiden  
The Netherlands

## **Adjuvant treatment for endometrial cancer: efficacy, toxicity and quality of life**

Boer, S.M. de

### **Citation**

Boer, S. M. de. (2019, November 12). *Adjuvant treatment for endometrial cancer: efficacy, toxicity and quality of life*. Retrieved from <https://hdl.handle.net/1887/80330>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/80330>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:  
<http://hdl.handle.net/1887/80330>

**Author:** Boer, S.M. de

**Title:** Adjuvant treatment for endometrial cancer: efficacy, toxicity and quality of life

**Issue Date:** 2019-11-12

## **AUTHOR AFFILIATIONS**

### **The Netherlands**

#### ***Leiden University Medical Center, Leiden***

*Department of Radiation Oncology*

Stephanie M. de Boer, Bastiaan G. Wortman, Remi A. Nout, Carien L. Creutzberg

*Department of Pathology*

Tjalling Bosse, Vincent T.H.B.M. Smit

*Department of Medical Statistics*

Hein Putter

#### ***University Medical Center Utrecht***

*Department of Radiation Oncology*

Ina M. Jürgenliemk-Schulz

#### ***Medisch Spectrum Twente, Enschede***

*Department of Radiation Oncology*

Jan J. Jobsen

#### ***Maastricht University Medical Centre, Maastricht***

*Department of Radiation Oncology*

Ludy C.H.W. Lutgens

*Department of Obstetrics and Gynaecology and GROW - School for Oncology and Developmental Biology*

Roy F. Kruitwagen

#### ***Radiotherapy Group Arnhem***

Elzbieta M. van der Steen-Banasik

#### ***ErasmusMC-Daniel den Hoed Cancer Center, Rotterdam***

*Department of Radiation Oncology*

Jan Willem M. Mens

#### ***Radiotherapy Institute Friesland, Leeuwarden***

Annerie Slot

**Radiotherapy Group Deventer**

Marika C. Stenfert Kroese, Sandrine M.G. van de Pol

**Netherlands Comprehensive Cancer Organisation**

*Research Department Eindhoven and Center of Research on Psychology in Somatic Diseases*

Simone Oerlemans

**Comprehensive Cancer Center The Netherlands, Leiden**

Karen W. Verhoeven-Adema

**University Medical Center Groningen, Groningen**

*Department of Gynaecologic Oncology*

Hans W. Nijman

*Department of Pathology*

Harry Hollema

*Department of Radiation Oncology*

Elizabeth Pras

**Radboudumc, Nijmegen**

*Department of Medical Oncology*

Petronella B. Ottevanger

*Department of Radiation Oncology*

An Snyers

**Amsterdam University Medical Center, AMC**

*Department of Radiation Oncology*

Henrike Westerveld

**Haaglanden Medical Center**

*Department of Radiation Oncology*

Tanja C. Stam

**Netherlands Cancer Institute, Amsterdam**

*Department of Radiation Oncology*

Baukelien van Triest, Monique Bloemers

**Radiotherapy Institute Verbeeten, Tilburg**

Karin A.J. de Winter

**Catharina Hospital, Eindhoven**

*Department of Radiation Oncology*

Hetty A. van den Berg

**United Kingdom****Barts Health NHS Trust, London**

*Department of Clinical Oncology*

Melanie E. Powell

*Department of Cellular Pathology*

Naveena Singh, Munaib N. Chowdhury

**Cancer Research UK and UCL Cancer Institute, London**

Jonathan A. Ledermann, Amanda Feeney

**University of Manchester, Manchester**

*Institute of Cancer Sciences*

Henry C. Kitchener

**Central Manchester Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester**

*Department of Pathology*

Godfrey Wilson

**Australia & New Zealand****Peter MacCallum Cancer Centre, Melbourne, VIC**

*Division of Cancer Medicine*

Linda Mileschkin

*Division of Radiation Oncology*

Pearly Khaw

**Auckland City Hospital, Auckland**

*Department of Radiation Oncology*

Susan Brooks

**Liverpool Cancer Therapy Centre, Liverpool**

*Department of Radiation Oncology*

Viet Do

**Royal Women's Hospital, Victoria**

*Department of Anatomical Pathology*

Jan Pyman

**The University of Sydney, Sydney**

*NHMRC Clinical Trials Centre*

Ilka Kolodziej

**Italy**

**Città della Salute and S Anna Hospital, University of Turin, Turin**

*Department of Surgical Sciences, Gynecologic Oncology*

Dionyssios Katsaros

**ASST-Lecco, Ospedale AManzoni, Lecco**

*Division of Radiation Oncology*

Alessandro Colombo, Romerai D'Amico

**A.O.U. Città della Salute e della Scienza di Torino, Turin**

*Department of Oncology – Radiotherapy*

Sergio Gribaudo

**San Gerardo Hospital, University of Milano-Bicocca, Monza**

*Department of Obstetrics and Gynecology, Gynecologic Oncology Unit*

Andrea Lissoni

**European Institute of Pathology, Milan**

*Division of Pathology and Laboratory Medicine*

Silvestro Carinelli

**Canada****University of Sherbrooke, Sherbrooke, QC**

*CCTG, Department of Obstetrics and Gynaecology*

Paul Bessette

**Princess Margaret Cancer Centre, Toronto**

*CCTG, Radiation Medicine Program*

Anthony Fyles

**Hôpital Notre-Dame de Montreal, Montreal, QC**

*Department of Gynaecologic Oncology*

Diane Provencher

**Western University, London**

*Department of Pathology and Laboratory Medicine*

Meg C.M. McLachlin

**France****Institut Gustave Roussy, Villejuif**

*Department of Radiation Oncology*

Christine Haie-Meder

*Department of Pathology*

Pierre Duvillard

**Centre Hospitalier Régional Universitaire de Besançon, Besançon**

*Department of Radiation Oncology*

Marie-Helene Baron

**Centre Henri Becquerel, Rouen**

*Department of Radiation Oncology*

Chantal Hanzen





## **PORTEC-3 PARTICIPATING GROUPS AND CENTRES**

### **PORTEC-3 Independent data monitoring committee:**

L.V.A.M. Beex, N. James, M.J.M. Olofsen-van Acht, W. Parulekar, W.L.J. van Putten, D. Rischin, J. Yarnold (chair)

**PORTEC-3 trial statistician:** H. Putter

### **List of participating countries and centres (listed in order of patients recruited)**

#### **United Kingdom: 184 patients (177 evaluable)**

*Study Coordinators:* M. Powell (P.I.), London; H. Kitchener, Manchester; J. Ledermann, London

*Group coordinating trial centre:* Cancer Research UK and UCL Cancer Trials Centre, London

*Trial pathologists:* N. Singh, London; G. Wilson, Manchester

*Participating centres and principal investigator(s) (number of patients):*

London-Barts Health NHS Trust (M. Powell, 23); London-University College London Hospitals NHS Foundation Trust (M. McCormack, 15); Bebington, Wirral-The Clatterbridge Cancer Centre NHS Foundation Trust (K. Whitmarsh, K. Hyatt, 12); Wolverhampton-The Royal Wolverhampton NHS Trust (R. Allerton, 11); Cambridge-Cambridge University Hospitals NHS Foundation Trust (L.T. Tan, M. Iddawela, D. Gregory, S. Ayres, 11); Leicester-Leicester Royal Infirmary (P. Symonds, 10); Northwood-Mount Vernon Cancer Centre (P. Hoskin, 10); Middlesbrough-The James Cook University Hospital (A. Rathmell, M. Adusumalli, 9); Nottingham-Nottingham City Hospital (S. Chan, A Anand, 9); Norwich-Norfolk and Norwich University Hospitals NHS Foundation Trust (R. Wade, 8); Guildford-Royal Surrey County Hospital (A. Stewart, 6); Newcastle Upon Tyne-Freeman Hospital (W. Taylor, 6); Brighton-Brighton & Sussex University Hospitals NHS Trust (K. Lankester, 5); Coventry-University Hospital Coventry (C. Irwin, M. Hocking, 5); Taunton-Musgrove Park Hospital (P. Jankowska, D. Milliken, C. Barlow, 5); Cheltenham-Cheltenham General Hospital (A. Cook, R. Counsell, 4); Exeter-Royal Devon & Exeter Hospital (P. Bliss, A. Hong, 4); Lincoln-Lincoln County Hospital (M. Panades, 4); Romford-Queens Hospital (M. Quigley, 4); Manchester-The Christie NHS Foundation Trust (S. Davidson, 3); Northampton-Northampton General Hospital NHS Trust (C. Mak, 3); Preston-Royal Preston Hospital (A. Hindley, 3); Truro-Royal Cornwall Hospitals NHS Trust (A. Thomson, 3); Sheffield-Weston Park Hospital (S. Pledge, J. Martin, 2); Shrewsbury-Royal Shrewsbury Hospital (S. Awwad, A. Zachariah, 2); Carlisle-North Cumbria University Hospitals NHS Trust (S. Singhal, 1); Colchester-Essex County Hospital (A. Lamont, 1); London-Guy's and St. Thomas' NHS Foundation Trust (A. Winship, A. Montes, V. Mullassery, 1); London-Hammersmith Hospital - Imperial College Healthcare NHS Trust (A. Taylor, 1); Poole-Poole Hospital NHS

Foundation Trust (V. Laurence, M. Flubacher, 1); Reading-Royal Berkshire Hospital (H. O'Donnell, 1); Stoke-on-Trent-Royal Stoke University Hospital (R. Bhana, S. Lupton, 1)

### **The Netherlands: 145 patients (138 evaluable)**

*Study Coordinators:* C.L. Creutzberg (C.I.), Leiden; R. Kruitwagen, Maastricht; H. Nijman, Groningen; N. Ottevanger, Nijmegen

*Group coordinating trial centre:* Netherlands Comprehensive Cancer Organisation (IKNL), Leiden

*Trial pathologists:* H. Hollema, Groningen; V.T. Smit, Leiden

*Participating centres and principal investigator(s) (number of patients):*

University Medical Center Utrecht (I.M. Jurgenliemk-Schulz, 20); Maastricht Clinic, Maastricht (L.C.H.W. Lutgens, 17); University Medical Center Groningen (E. Pras, 15); Leiden University Medical Center (C.L. Creutzberg, R. Nout, 15); University Medical Center Radboud, Nijmegen (J.W.H. Leer, A. Snyers, 11); Academic Medical Center, Amsterdam (A.L.J. Uitterhoeve, G.H. Westerveld, 9); Medical Spectre Twente, Enschede (J.J. Jobsen, 9); Radiotherapy institute Friesland, Leeuwarden (A. Slot, 9); Erasmus Medical Center Rotterdam (J.W.M. Mens, 8); Medical Center Haaglanden/ Radiotherapy Centre West (T.C. Stam, P.C.M. Koper, 7); Netherlands Cancer Institute, Amsterdam (B. van Triest, 6); Radiotherapy Group, Arnhem (E.M. van der Steen-Banasik, 6); Radiotherapy Institute Verbeeten, Tilburg (K.A.J. de Winter, 6); Radiotherapy Group, Deventer (S. van de Pol, 3); Catharina Hospital, Eindhoven (H.A. van den Berg, 3); VU Medical Centre, Amsterdam (O.W.M. Meijer, 1)

### **Australia & New Zealand: 122 patients (118 evaluable)**

*ANZGOG Study Coordinators:* L. Mileschkin (P.I.) Melbourne; M. Quinn, Melbourne; P. Khaw Melbourne; I. Kolodziej, Sydney

*Group coordinating trial centre:* NHMRC Clinical Trials Centre, Sydney

*Trial pathologist:* J. Pyman, Melbourne

*Participating centres and principal investigator(s) (number of patients):*

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia (L. Mileschkin, P. Khaw; 31); Monash Cancer Centre (Monash Medical Centre), East Bentleigh, Victoria, Australia (P. Khaw/G. Goss, 20); Westmead Hospital, Wentworthville, NSW, Australia (G. Wain, 15); Auckland City Hospital, Auckland, New Zealand (S. Brooks, 13); Wellington Blood & Cancer Centre, Wellington, New Zealand (C. Johnson, 11); Calvary Mater Newcastle, Newcastle, Australia (A. Capp, 8); Christchurch Hospital, Canterbury, New Zealand (M. Vaughan, 4); Royal Hobart Hospital, Hobart, Tasmania, Australia (P. Blomfield, 3); Palmerston North Hospital, Palmerston North, New Zealand (C. Hardie, 3); Royal North Shore Hospital, St Leonards, NSW, Australia (M. Stevens, 3); Waikato Hospital, Hamilton, New Zealand (M. Kuper, 2); Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia (R.

Cheuk, 2); Liverpool Hospital, Liverpool, NSW, Australia (S. Vinod, 2); Mater Hospital Brisbane, South Brisbane, QLD, Australia (C. Shannon/J. Ramsay, 2); Wollongong Hospital, Wollongong, NSW, Australia (A. Glasgow, 2); Townsville Hospital, Townsville, QLD, Australia (S. Hewitt, 1)

### **Italy: 103 patients (98 evaluable)**

*MaNGO Study Coordinators:* R. Fossati (P.I.) Milano; D. Katsaros, Torino; A. Colombo, Lecco  
*Group coordinating trial centre:* Istituto di Ricerche Farmacologiche Mario Negri, Milano  
*Trial pathologists:* S. Carinelli, Milano; C. Di Tonno, Milano

*Participating centres and principal investigator(s) (number of patients):*

Torino - S. Anna Hospital (S. Gribaudo, M. Mitidieri, 33); Lecco - Ospedale A. Manzoni (R. D'Amico, 24); Monza - S. Gerardo Hospital (S. Meregalli, A. A. Lissoni, 16); Torino - Ospedale Umberto I (A. Ferrero, 7); Padova - Istituto Oncologico Veneto / Mirano, Venezia - Azienda ULSS 13 (L. Corti, G. Artioli, 6); Varese - H. Del Ponte University of Insubria (C. Apolloni, 4); Ravenna - Ospedale S. Maria delle Croci (D. Turci, 4); Brescia - Spedali Civili (G. Tognon, 2); Como - ASST Lariana Ospedale S. Anna (E. Bianchi, 2); Meldola - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (E. Bianchi, 2); Genova - IRCCS San Martino IST (M. Bruzzone, 1); Milano - ASST Grande Ospedale Metropolitano Niguarda (S. Siena, 1); Palermo - AOR Villa Sofia-Cervello (N. Varsellona, 1)

### **Canada: 65 patients (65 evaluable)**

*CCTG Study Coordinators:* A. Fyles Toronto, Ontario; P. Bessette, Sherbrooke, Quebec  
*Group coordinating trial centre:* Canadian Cancer Trials Group, Kingston, Ontario  
*Trial pathologist:* M. McLachlin, London, Ontario

*Participating centres and principal investigator(s) (number of patients):*

Sherbrooke-Centre Hosp. Universitaire de Sherbrooke (P. Bessette, 18); Montreal-Hopital Notre-Dame de Montreal (D. Provencher, 11); Calgary-Tom Baker Cancer Centre (P. Ghatage, 9); Halifax-Queen Elizabeth II Health Sciences Centre (P. Rittenberg, 8); Montreal-McGill Oncology Montreal (L. Souhami, 7); Toronto-Sunnybrook Health Sciences Centre (G. Thomas, 7); Quebec-Hotel-Dieu de Quebec (M. Plante, 2); London-London Health Sciences Centre (A. Hammond, 1); St John's-Dr. H. Bliss Murphy Cancer Centre (P. Power, 1); Toronto-Princess Margaret Hospital (A. Fyles, 1)

### **France: 67 patients (64 evaluable)**

*FEDEGYN Study Coordinator:* Chr. Haie-Meder (P.I.) Paris

*Group coordinating trial centre:* UNICANCER, Paris

*Trial pathologist:* P. Duvillard, Paris

*Participating centres and principal investigator(s) (number of patients):*

Besancon-Hopital Jean Minjoz (M-H Baron, 10); Rouen-Centre Henri Becquerel (Hanzen, 9); Saint Herblain-Centre Rene Gauducheau (D. Berton-Rigaud, 8); Limoges-CHU Limoges (Pr. N. Tubiana-Mathieu, 6); Bordeaux-Institut Bergonie (L. Thomas, 5); Reims-Institut Jean Godinot (A. Savoye, S. Maillard, 5); Dijon-Centre Georges Francois Leclerc (K. Peignaux, 4); Paris/ Villejuif-Institut Gustave Roussy (C. Haie Meder, 4); Clermont-Ferrand-Centre Jean Perrin (C. Benoit, 3); Montpellier-Centre Val d'Aurelle (C. Kerr, 3); Toulouse Cedex-Institut Claudius Regaud (L. Gladieff, 3); Caen-Centre Francois Baclesse (D. Lerouge, 2); Nice Cedex-Centre Antoine Lacassagne (P. Follana, 2); Marseille-Institut Paoli Calmettes (M. Capiello, 1); Strasbourg-Centre Paul Strauss (T. Petit, 1); Tours Cedex-CHU de Tours - Hopital Bretonneau (I. Barillot, 1)

## LIST OF PUBLICATIONS AND CONFERENCE PRESENTATIONS

### Publications

**de Boer, S.M.**, M.E. Powell, L. Mileshekin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, R. D'Amico, A. Fyles, M.H. Baron, I.M. Jurgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, S. Brooks, S. Gribaudo, D. Provencher, C. Hanzen, R.F. Kruitwagen, V. Smit, N. Singh, V. Do, A. Lissoni, R.A. Nout, A. Feeney, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; Patterns of recurrence and updated survival outcomes in the randomised PORTEC-3 trial of adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer; *Lancet Oncol.* Epub 22 July 2019

**de Boer, S.M.**, R.A. Nout, C.L. Creutzberg; Adjuvante behandeling van hoog-risico endometriumcarcinoom: update van recente gerandomiseerde trials; *NTVO*. Accepted.

**de Boer S.M.**, R.A. Nout, T. Bosse, C.L. Creutzberg; Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions; *Expert Rev Anticancer Ther.* 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24.

Wortman, B.G., C.L. Creutzberg, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, L. Lutgens, E.M. van der Steen-Banasik, J.W.M. Mens, A. Slot, M.C. S. Kroese, B. van Triest, H.W. Nijman, E. Stelloo, T. Bosse, **S.M. de Boer**, W.L.J. van Putten, V. Smit, R.A. Nout; PORTEC Study Group; Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy; *Br J Cancer.* 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

Nout, R.A., M.E. Powell, **S.M. de Boer**, C.L. Creutzberg (2018) Investigators' response. *Lancet Oncol*, 19, 602.

**de Boer, S.M.**, M.E. Powell, L. Mileshekin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jurgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, S. Brooks, S. Carinelli, D. Provencher, C. Hanzen, L. Lutgens, V. Smit, N. Singh, V. Do, R. D'Amico, R.A. Nout, A. Feeney, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncology* 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2.

**de Boer, S.M.**, B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshekin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. *Annals of Oncology* 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753

**de Boer, S.M.**, M.E. Powell, L. Mileshekin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, R.A. Nout, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. *The Lancet Oncology* 2016; 17(8): 1114-26. [http://dx.doi.org/10.1016/S1470-2045\(16\)30120-6](http://dx.doi.org/10.1016/S1470-2045(16)30120-6).

**de Boer, S.M.**, R.A. Nout, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C. Lutgens, E.M. van der Steen-Banasik, J.W. Mens, A. Slot, M.C. Stenfert Kroese, S. Oerlemans, H. Putter, K.W. Verhoeven-Adema, H.W. Nijman, C.L. Creutzberg; Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial; *Int J Radiat Oncol Biol Phys.* 2015 Nov 15;93(4):797-809

de Graaf, F.R., J.E. van Velzen, **S.M. de Boer**, J.M. van Werkhoven, L.J. Kroft, A. de Roos, A. Sieders, G.J. de Grooth, J.W. Jukema, J.D. Schuijf, J.J. Bax, M.J. Schalij, E.E van der Wall; Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography *Int J Cardiovasc Imaging.* 2012 May 11

van Werkhoven J.M.\* MSc, **S.M. de Boer\***, J.D. Schuijf, F. Cademartiri, E. Maffei, J.W. Jukema, M.J. Boogers, L.J. Kroft, A. de Roos, J.J. Bax; Impact of Clinical Presentation and Pre-Test Likelihood on the Relation between Calcium Score and Computed Tomography Coronary Angiography; *Am J Cardiol.* 2010 Dec 15;106(12):1675-9. Epub 2010 Nov 4)

\*Dr. van Werkhoven and Ms. de Boer contributed equally to this work.

### Conference presentations

*American Society for Radiation Oncology (ASTRO) annual meeting 2019 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L. Mileshekin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, V.T. Smit, R.A. Nout, H. Putter, C.L.

Creutzberg; Patterns of recurrence and survival in the randomized PORTEC-3 trial of chemoradiotherapy for high-risk endometrial cancer.

*Gynaecology congress of the Dutch Society of Obstetrics and Gynaecology (NVOG) 2019 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, V.T. Smit, R.A. Nout, H. Putter, C.L. Creutzberg; Update of survival outcomes in the PORTEC-3 trial

*European Society Radiation Oncology (ESTRO) annual meeting 2018 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, I. Kolodziej, S. Carinelli, L.C.H.W. Lutgens, V.T.H.B.M. Smit, N. Singh, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; OC-0323: Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer.

*European Congress of Pathology (ECP) annual meeting 2017 (oral presentation)*

**de Boer, S.M.**, B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer.

*Scientific meeting of the Dutch Society for Radiotherapy and Oncology (NVRO) 2017 (oral presentation)*

**de Boer, S.M.**, B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; The value of upfront pathology review in the PORTEC-3 trial.

*American Society of Clinical Oncology (ASCO) annual meeting 2017 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L.R. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A.W. Fyles, M-H. Baron, H.C. Kitchener, H.W. Nijman, R.F.P.M. Kruitwagen, I.M. Jürgenliemk-Schulz, R.A. Nout, V.T.H.B.M. Smit, H. Putter, C.L. Creutzberg; Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

*International Gynecologic Cancer Society (IGCS) biannual meeting 2016 (poster)*

**de Boer, S.M.**, B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer.

*Dutch Gynaecology Oncology Group symposium 2016 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen, J.A. Ledermann, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: first results of the randomised PORTEC-3 trial.

*Scientific meeting of the Dutch Society for Radiotherapy and Oncology (NVRO) 2015 (oral presentation)*

**de Boer, S.M.**, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen, J.A. Ledermann, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: first results of the randomised PORTEC-3 trial.

*European Society Gynaecologic Oncology (ESGO) biannual meeting 2015 (poster)*

**de Boer, S.M.**, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen, J.A. Ledermann, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Relation between patient and physician reported toxicity in the randomised PORTEC-3 trial of radiation therapy (RT) with or without chemotherapy for endometrial cancer.

*European Society Radiation Oncology (ESTRO) annual meeting (poster presentation)*

**de Boer, S.M.**, R.A. Nout, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.W. Lutgens, E.M. Van der Steen-Banasik, J.W.M. Mens, A. Slot, M.C. Stenfert Kroese, H.W. Nijman, C.L. Creutzberg; Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial.



## CURRICULUM VITAE

Stephanie de Boer werd op 28 november 1986 geboren in Naarden. In 2005 behaalde zij haar Gymnasium diploma aan het Willem de Zwijgercollege te Bussum, waarna zij startte met de studie geneeskunde aan de Universiteit Leiden. Tijdens haar studie heeft zij een klinische stage (interne geneeskunde) gevolgd in het Dr. Moewardi Hospital in Surakarta, Indonesie, en heeft zij haar laatste keuzecoschap tropengeneeskunde in het St Joseph Hospital, Kagondo, Tanzania, afgerond. In 2009 heeft zij wetenschappelijke stage gedaan op de afdeling Cardiologie in het Leids Universitair Medisch Centrum. Na het behalen van haar artsexamen in 2012 (cum laude) heeft ze een jaar in het Bronovo ziekenhuis te Den Haag gewerkt als arts-assistent (ANIOS) op de afdeling interne geneeskunde.

In oktober 2013 is zij gestart met de opleiding tot Radiotherapeut-Oncoloog in het Leids Universitair Medisch Centrum (opleiders: prof. dr. C.A.M. Marijnen en prof dr. C.L. Creutzberg), en gedurende 14 maanden in het Haaglanden Medisch Centrum (opleiders: dr. R. Wiggeraad en dr. A.Y. Verbeek-de Kanter). Tijdens haar opleiding startte zij in 2014 met onderzoek naar de lange termijn kwaliteit van leven in de PORTEC-2 studie en naar de uitkomsten van de PORTEC-3 studie onder begeleiding van prof. dr. C.L. Creutzberg en dr. R.A. Nout. In 2016 heeft zij in het Verenigd Koninkrijk (Barts and the London NHS Trust, London en Manchester Royal Infirmary Hospital, Manchester, begeleider dr. N. Singh) onderzoek gedaan naar de centrale pathologie revisie in de PORTEC-3 studie, waarvoor zij een reisbeurs van het Leids Universiteits Fonds ontving. In het kader van de studies in dit proefschrift bezocht ze diverse congressen in het binnen- en buitenland waar ze meerdere presentaties gaf.

Stephanie zal op 31 december 2019 haar opleiding afronden en zij zal per 1 januari 2020 starten als Radiotherapeut-Oncoloog in het Leids Universitair Medisch Centrum. Dit zal zij blijven combineren met onderzoek binnen de gynaecologiegroep, het PORTEC- en het TransPORTEC consortium.

Stephanie is getrouwd met Jesse Bank en samen hebben zij een dochter, Mila.



## DANKWOORD

Allereerst wil ik alle vrouwen bedanken die hebben deelgenomen aan de PORTEC-studies. Zonder hen was dit onderzoek niet mogelijk geweest. Verder wil ik graag alle collega's in het binnen en buitenland bedanken die hebben bijgedragen aan de totstandkoming van de studies in dit proefschrift. De leden van de promotiecommissie bedank ik voor hun kritische blik en tijd.

Without the strong, successful international collaboration the PORTEC-3 trial would never have been possible. Many thanks to the participating groups, their coordinating teams, principal investigators, staff, clinical research teams, the PORTEC-3 data safety monitoring board for all of your support for the PORTEC-3 trial.

Een aantal mensen wil ik graag in het bijzonder bedanken:

Mijn promotor prof dr. C.L. Creutzberg, Carien, voor het vertrouwen en de kans die je mij hebt geboden om dit proefschrift te mogen schrijven en ervaring op te mogen doen in de mooie onderzoeksgroep (trans)PORTEC. Je eindeloze enthousiasme, energie en kennis zijn ongekend, en je laagdrempelige begeleiding waardeer ik enorm.

Mijn co-promotor dr. R.A. Nout, Remi, voor je enthousiaste begeleiding en je kritische blik op het onderzoek.

Prof. dr. H. Putter, Hein, voor je statistische hulp en onderricht, en het maken van de vele mooie figuren.

Dr. K.W. Verhoeven-Adema, Karen, voor alle tijd en energie die je in de PORTEC-3 studie hebt gestoken om de internationale data compleet te krijgen, de prettige samenwerking en je hulp bij de vele queries.

Prof. dr. V.T.H.B.M. Smit en dr. T. Bosse, Vincent en Tjalling, jullie enthousiasme voor de ontwikkelingen binnen de gynaecopathologie is aanstekelijk en motiverend. Bedankt voor al jullie hulp en inspirerende samenwerking: op naar nog vele mooie ontwikkelingen binnen de (trans)PORTEC studies.

Prof. dr. C.A.M. Marijnen, Corrie, voor de kans die je me hebt geboden om gelijktijdig mijn opleiding en promotie onderzoek te mogen doen. Ik heb veel van je geleerd en ik waardeer je adviezen zeer.

Alle collega's van de afdeling radiotherapie, en in het bijzonder de AIOS voor jullie support en de fijne samenwerking.

Mijn (schoon-)familie, vrienden, mijn ouders, Jesse en Mila, voor jullie steun en vertrouwen, maar ook voor de broodnodige ontspanning en afleiding!

